Nektar Therapeutics.
American healthcare company
- Reports this week
- 1
- Active events
- 1
- Connections
- 57
What's happening
Active this week
Earlier this month
One to three months ago
-
Leerink Partners assumed coverage on Nektar Therapeutics shares on October 13, 2026.Some support2 reports
-
Multiple financial firms, including KBC Group NV, WINTON GROUP Ltd, and Deutsche Bank, increased their stakes in Nektar Therapeutics on September 12, 2026.Some support1 report
-
Market factors drive comparative business analysis between Nektar Therapeutics and Janux Therapeutics.Some support2 reports
-
Nathan Miller is associated with an investigation involving Nektar Therapeutics.Some support2 reports
-
Nektar Therapeutics is seeking FDA review for its late-stage drug trials.Some support1 report
-
Nektar Therapeutics filed a registration statement with the SEC on July 3, 2025.Some support4 reports1 development inside
-
Nektar Therapeutics is seeking alignment with the FDA for its registrational Phase III study.Some support1 report
Gone quiet
No new reports in 90+ days-
TD Cowen began coverage of Nektar Therapeutics on July 2, 2026, coinciding with an insider selling 5,538 shares of the company's stock.Some support1 report
-
Nektar Therapeutics and Journey Medical are being compared for investment, with Nektar showing stronger consensus rating and upside.Some support1 report
-
Nektar Therapeutics filed required disclosures with the SEC on June 20, 2026.Some support1 report
-
Nektar Therapeutics is headquartered in San Francisco and its pipeline includes a modified CSF protein.Speculative1 report
-
Nektar Therapeutics noted a potential benefit from Trump-era tariffs and onshoring policies.Speculative1 report
-
Nektar Therapeutics' stock doubled following the release of positive trial results.Speculative1 report
-
BTIG raised its price target for Nektar Therapeutics on June 25, 2025.Speculative1 report
-
Nektar Therapeutics announced on July 29, 2025, that a treatment they are developing showed promise by utilizing a unique Treg mechanism.Some support1 report
-
Nektar Therapeutics is headquartered in San Francisco and participated in a conference in New York City on September 4, 2025.Some support3 reports
-
Nektar Therapeutics regained full rights to its rezpeg program from Eli Lilly and Company on August 4, 2025.Some support1 report
-
Nektar Therapeutics received FDA Fast Track designation and saw its stock gain exceed the S&P 500 index gain on August 9, 2025.Well supported3 reports
-
Howard W. Robin was appointed President and CEO of Nektar Therapeutics on August 8, 2025.Some support2 reports
-
Sanofi's disappointing results cleared the way for Nektar Therapeutics.Some support1 report
No events began in the chosen period. Widen it, or reset.
Around Nektar Therapeutics this week
News at the entities that move Nektar Therapeutics most-
FDA StructuralFDA issued a warning letter to NeoGen regarding a product quality defect on October 7, 2026.Moves Nektar Therapeutics
-
MarketBeat Mentioned togetherDanske Bank and Farmers & Merchants Bancorp Inc. are being compared as finance companies, with MarketBeat providing analyst ratings for the latter.Moves Nektar Therapeutics
-
board of directors StructuralGagne was appointed to represent Franklin County on the VMSMA Board.Moves Nektar Therapeutics
-
SEC StructuralMSCI index rules may affect Bitcoin companies, while warnings caused stock market crashes in Turkey and Indonesia.Moves Nektar Therapeutics
-
Leerink partners Mentioned togetherLeerink partners, TD Cowen, and William Blair initiated coverage and set ratings for Kailera Therapeutics.Moves Nektar Therapeutics
-
TD Cowen Mentioned togetherTD Cowen is based in Toronto.Moves Nektar Therapeutics
Connections
The 16 strongest of 57, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
FDA Structural
The FDA is formally regulating and evaluating Nektar Therapeutics' drug candidates, including granting Fast Track designation.
-
SEC Structural
Nektar Therapeutics is formally regulated by the SEC, requiring company filings and disclosures to operate.
-
CSF Structural
Nektar Therapeutics utilizes the CSF protein in its development and pipeline.
-
board of directors Structural
The Board of Directors governs Nektar Therapeutics, demonstrated by the Board granting stock options to new employees.
-
MarketBeat Mentioned together
MarketBeat reports consensus ratings and price targets for Nektar Therapeutics.
-
Eli Lilly and Company Transactional
Nektar Therapeutics regained full rights to the rezpeg asset from Eli Lilly and Company in 2025.
-
Corey Davis Structural
Corey Davis serves as a listed contact for investors of Nektar Therapeutics.
-
Jonathan Zalevsky Structural
Jonathan Zalevsky is an insider of Nektar Therapeutics, evidenced by stock sales.
Show all 16 connections
-
Vivian Wu Structural
Vivian Wu serves as an investor contact for Nektar Therapeutics.
-
Leerink partners Mentioned together
Leerink Partners provides assumed financial coverage on Nektar Therapeutics shares.
-
TD Cowen Mentioned together
TD Cowen has initiated market coverage of Nektar Therapeutics.
-
LinkedIn Mentioned together
Nektar Therapeutics uses LinkedIn as a platform to follow and gather information.
-
Nathan Miller Operational
Nathan Miller is associated with an investigation concerning Nektar Therapeutics.
-
London Shared context
Nektar Therapeutics' management conducts activities, such as attending conferences, within the geographical context of London.
-
Huntsville Shared context
Nektar Therapeutics operates a manufacturing facility located in Huntsville.
-
San Francisco Shared context
Nektar Therapeutics is headquartered in San Francisco.
History
Events by the month they beganNovember 2026
2 eventsOctober 2026
2 eventsSeptember 2026
2 eventsShow 3 earlier months
August 2026
3 eventsJuly 2026
1 eventJune 2026
13 events- Nektar Therapeutics filed a registration statement with the SEC on July 3, 2025.
- Nektar Therapeutics and Journey Medical are being compared for investment, with Nektar showing stronger consensus rating and upside.
- Nektar Therapeutics filed required disclosures with the SEC on June 20, 2026.
- Nektar Therapeutics is headquartered in San Francisco and its pipeline includes a modified CSF protein.
- Nektar Therapeutics noted a potential benefit from Trump-era tariffs and onshoring policies.
- Nektar Therapeutics' stock doubled following the release of positive trial results.
- BTIG raised its price target for Nektar Therapeutics on June 25, 2025.
- Nektar Therapeutics announced on July 29, 2025, that a treatment they are developing showed promise by utilizing a unique Treg mechanism.
- Nektar Therapeutics is headquartered in San Francisco and participated in a conference in New York City on September 4, 2025.
- Nektar Therapeutics regained full rights to its rezpeg program from Eli Lilly and Company on August 4, 2025.
- Nektar Therapeutics received FDA Fast Track designation and saw its stock gain exceed the S&P 500 index gain on August 9, 2025.
- Howard W. Robin was appointed President and CEO of Nektar Therapeutics on August 8, 2025.
- Sanofi's disappointing results cleared the way for Nektar Therapeutics.